Abemaciclib + MK-6482
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Clear Cell Renal Cell Carcinoma
Conditions
Clear Cell Renal Cell Carcinoma
Trial Timeline
Dec 31, 2020 → Aug 4, 2024
NCT ID
NCT04627064About Abemaciclib + MK-6482
Abemaciclib + MK-6482 is a phase 1 stage product being developed by Eli Lilly for Clear Cell Renal Cell Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT04627064. Target conditions include Clear Cell Renal Cell Carcinoma.
What happened to similar drugs?
3 of 13 similar drugs in Clear Cell Renal Cell Carcinoma were approved
Approved (3) Terminated (1) Active (9)
✅nebulized albuterol (2.5 mg/3ml/dose) + nebulized levalbuterol (1.25 mg/3ml/dose) + nebulized placebo (3ml/dose)Sumitomo PharmaApproved
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04627064 | Phase 1 | Completed |
Competing Products
20 competing products in Clear Cell Renal Cell Carcinoma